Oral treatment for multiple sclerosis
- PMID: 22014437
- DOI: 10.1016/S1474-4422(11)70228-9
Oral treatment for multiple sclerosis
Abstract
Background: The armamentarium for the treatment of relapsing-remitting multiple sclerosis (RRMS) is increasing rapidly. Several oral treatments have shown benefit and will generate much interest because of the convenience of such administration. However, availability of convenient oral drugs will not necessarily translate into clinical effectiveness and safety. Here, we provide an interim report about the mechanisms of action, and efficacy and safety results that have been reported since January, 2010, for five new oral drugs. Additionally, we draw attention to issues that neurologists and patients will encounter when considering the use of new oral drugs.
Recent developments: Positive results have been reported for five new oral drugs for RRMS--fingolimod, cladribine, teriflunomide, laquinimod, and dimethyl fumarate--in phase 3 studies; a few new oral drugs are likely to be approved for RRMS soon. WHERE NEXT?: Emerging oral treatments are ushering in a new era in the treatment of MS, providing not only new treatment options but also new challenges. Since data for some of the new drugs have not been reported in peer-reviewed journals yet and safety profiles are not yet fully developed, opinions about the use of these new oral drugs in practice are preliminary and tentative. Practice will evolve with time as information and experience accumulates. Of importance will be results from comparator trials, information about management of patients with breakthrough disease, results from long-term safety studies, and results of studies to assess the potential for neuroprotective effects of the new drugs.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.Am J Health Syst Pharm. 2015 Jan 1;72(1):25-38. doi: 10.2146/ajhp140023. Am J Health Syst Pharm. 2015. PMID: 25511835 Review.
-
Emerging oral drugs for multiple sclerosis.Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465. Expert Opin Emerg Drugs. 2008. PMID: 18764723 Review.
-
[Oral treatments in multiple sclerosis].Med Clin (Barc). 2014 Dec;143 Suppl 3:23-9. doi: 10.1016/S0025-7753(15)30006-3. Med Clin (Barc). 2014. PMID: 25732946 Review. Spanish.
-
New oral drugs for multiple sclerosis.Neurol Sci. 2009 Oct;30 Suppl 2:S179-83. doi: 10.1007/s10072-009-0146-3. Neurol Sci. 2009. PMID: 19882371 Review.
-
Update on multiple sclerosis treatments.Swiss Med Wkly. 2014 Sep 23;144:w14012. doi: 10.4414/smw.2014.14012. eCollection 2014. Swiss Med Wkly. 2014. PMID: 25247669 Review.
Cited by
-
Study of fingolimod, nitric oxide inhibitor, and P-glycoprotein inhibitor in modulating the P-glycoprotein expression via an endothelin-sphingolipid pathway in an animal model of pharmacoresistant epilepsy.Indian J Pharmacol. 2023 Sep-Oct;55(5):307-314. doi: 10.4103/ijp.ijp_100_23. Indian J Pharmacol. 2023. PMID: 37929409 Free PMC article.
-
The effects and side effects of laquinimod for the treatment of multiple sclerosis patients: a systematic review and meta-analysis of clinical trials.Eur J Clin Pharmacol. 2020 May;76(5):611-622. doi: 10.1007/s00228-019-02827-6. Epub 2020 Feb 4. Eur J Clin Pharmacol. 2020. PMID: 32020320
-
Perspectives of Patients with Multiple Sclerosis on Drug Treatment: A Qualitative Study.Int J MS Care. 2018 Nov-Dec;20(6):269-277. doi: 10.7224/1537-2073.2017-109. Int J MS Care. 2018. PMID: 30568564 Free PMC article.
-
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.PLoS One. 2018 Mar 8;13(3):e0193986. doi: 10.1371/journal.pone.0193986. eCollection 2018. PLoS One. 2018. PMID: 29518148 Free PMC article.
-
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.Mult Scler J Exp Transl Clin. 2016 Sep 29;2:2055217316672242. doi: 10.1177/2055217316672242. eCollection 2016 Jan-Dec. Mult Scler J Exp Transl Clin. 2016. PMID: 28607740 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources